This review explores the current understanding of Nrf2 dysfunction in AD and discusses the therapeutic potential of concurrently modulating the Nrf2 and Bach1 pathways to tackle the complex nature of AD pathology. The gene discussed is BACH1; the disease is Alzheimer disease.